MENLO PARK, Calif.--(BUSINESS WIRE)--Sofinnova Investments, a biopharmaceutical investment firm, announced today the addition of Maha Radhakrishnan, M.D. to the investment team as an Executive Partner.

加利福尼亚州门洛帕克（商业新闻短讯）--生物制药投资公司Sofinnova Investments今天宣布，投资团队中增加了医学博士Maha Radhakrishnan作为执行合伙人。

Dr. Radhakrishnan is an accomplished industry executive with over 20 years of experience advancing large strategic portfolios across various therapeutic areas through product development and commercialization and overseeing the global medical strategy and operations within major biotechnology and pharmaceutical companies..

Radhakrishnan博士是一位多才多艺的行业高管，拥有超过20年的经验，通过产品开发和商业化推进各个治疗领域的大型战略组合，并监督主要生物技术和制药公司的全球医疗战略和运营。。

Prior to joining Sofinnova, Dr. Radhakrishnan was Chief Medical Officer of Biogen, responsible for the worldwide medical function. She was also senior vice president and global head of medical, primary care business unit at Sanofi, a global biopharmaceutical company focused on human health. At Sanofi, she led the function providing the medical strategy for diabetes and cardiovascular products and programs in development.

在加入Sofinnova之前，Radhakrishnan博士是Biogen的首席医疗官，负责全球医疗功能。她还是赛诺菲（一家专注于人类健康的全球生物制药公司）的高级副总裁兼医疗、初级保健业务部门全球负责人。在赛诺菲，她领导了为糖尿病和心血管产品和开发项目提供医疗策略的职能部门。

Prior, she held several leadership roles at Bioverativ Inc., Bristol Myers Squibb, United Health Group, and Cephalon..

在此之前，她曾在Bioverativ Inc.，Bristol-Myers Squibb，United Health Group和Cephalon担任过多个领导职务。。

“Intentional and strategic growth of our team is core to our success, I believe Maha will be an exceptional asset to the Sofinnova team and portfolio as she brings decades of drug development expertise,” said Jim Healy, M.D., PhD., Managing Partner of Sofinnova Investments. “Her breadth of knowledge and operational experience will be invaluable in guiding portfolio companies, from clinical-stage drug development to large-scale commercialization to bring novel therapies to patients.”.

医学博士吉姆·希利（JimHealy）说：“我们团队的有意和战略性增长是我们成功的核心，我相信玛哈（Maha）将成为索芬诺娃（Sofinnova）团队和投资组合的特殊资产，因为她带来了数十年的药物开发专业知识。”。，索芬诺娃投资管理合伙人。。

“I am thrilled to join the Sofinnova Investments team. This is a team with an incredible track record of focusing on robust science and high unmet medical needs,” said Dr. Radhakrishnan. “We share a strong commitment to developing innovative therapeutics and advancing companies with a goal to create transformative value for patients.

。“我们共同致力于开发创新疗法和推进公司，以期为患者创造变革性价值。

I look forward to leveraging my clinical, drug development, and commercialization experience to advance new and existing investment opportunities across Sofinnova’s portfolio.”.

我期待着利用我的临床、药物开发和商业化经验，在索芬诺娃的投资组合中推进新的和现有的投资机会。”。

Dr. Radhakrishnan received her M.D. in internal medicine with honors from the People’s Friendship University in Moscow, Russia in 1995, as well as a master's degree in Russian language.

Radhakrishnan博士于1995年获得俄罗斯莫斯科人民友谊大学内科医学博士学位，并获得俄语硕士学位。

About Sofinnova Investments

关于Sofinnova Investments

Sofinnova Investments is a healthcare investment firm committed to funding innovative products that aspire to meaningfully impact the lives of patients. We invest in both private and public equity companies. Sofinnova actively partners with entrepreneurs across all stages of company formation, we are long-term investors with extensive scientific expertise, vast industry knowledge, and a track record of helping forge the path from drug development and navigating the regulatory process to company building and IPO or M&A..

Sofinnova Investments是一家医疗保健投资公司，致力于资助创新产品，以期对患者的生活产生重大影响。我们投资于私人和公共股本公司。Sofinnova在公司成立的各个阶段都与企业家积极合作，我们是长期投资者，拥有广泛的科学专业知识，丰富的行业知识，并有助于开拓从药物开发和监管流程到公司建设和IPO或并购的道路。。

Founded in 1976, Sofinnova has a long legacy of building what we believe are great companies in both the U.S. and Europe with approximately $3.7B in assets under management and committed capital as of 6/30/2024. For more information, please visit www.sofinnova.com.

索芬诺娃成立于1976年，拥有悠久的历史，在美国和欧洲建立了我们认为是伟大的公司，截至2024年6月30日，其管理的资产和承诺资本约为37亿美元。有关更多信息，请访问www.sofinnova.com。